Plus Therapeutics, Inc. presented data from two ongoing clinical trials evaluating the Company’s lead investigational targeted radiotherapeutic, rhenium obisbemeda, in recurrent glioblastoma, leptomeningeal metastases, as well as clinical trial plans for pediatric brain cancer at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology.
November 19, 2022
· 8 min read
